Trial Site Detail

 

Drug:
Rogaratinib
Trial:
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Conditions: Sarcoma
Trial Status:
Completed

 

Dana Farber Cancer Institute

450 Brookline Ave     
Boston , MA 02215-5450
USA

 

Principal Investigator:
Suzanne George
Contact:
Site Public Contact 877-442-3324
Activation Status of this Site:
Active
Notes about this Site:
Dana Farber Cancer Institute Website:
http://www.dana-farber.org/Research/Clinical-Trials.aspx

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.